on CannaPharmaRx (NASDAQ:CPMD)
CannaPharmaRX Reveals 2026 Growth Strategy amid Global Expansion
CannaPharmaRX, Inc., a key player in cannabis cultivation and export, has announced its strategic plans for 2026. The company is ramping up its international export operations with additional shipments to Israel, while developing new strains such as Black Candyland and Sour Chillz, aimed at the German medical cannabis market.
In 2026, CannaPharmaRX intends to increase its European export capacity by constructing new cultivation and drying facilities, compliant with EU-GMP standards. These investments aim to support expanded supply to Germany and other European markets.
The previously imposed trade restrictions by the British Columbia Securities Commission have been lifted, facilitating these expansion efforts. CannaPharmaRX remains cautious, highlighting the forward-looking nature of their growth projections.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all CannaPharmaRx news